Core Insights - Humacyte, Inc. reported total revenues of $0.5 million for Q4 2025 and $2.0 million for the full year, with significant growth in product sales and collaborations [1][11] - The company received a purchase commitment of $1.475 million for a clinical evaluation program in Saudi Arabia, indicating strong international interest in its product, Symvess [1][4] - A Marketing Authorization Application for Symvess has been submitted to the Israel Ministry of Health, expanding its market reach [1][5] - The U.S. Department of Defense has authorized funding for the procurement of bioengineered blood vessels, highlighting the product's relevance for military applications [1][4] - An important milestone is expected in Q2 2026 with the announcement of top-line interim results from the V012 Phase 3 study in hemodialysis access [1][3] Financial Performance - Revenue for Q4 2025 was $0.5 million, with $0.4 million from U.S. sales of 25 Symvess units and $0.1 million from a research collaboration [11][29] - For the full year 2025, revenue totaled $2.0 million, with $1.4 million from U.S. sales of 61 Symvess units and $0.6 million from research collaborations [11][29] - Cost of goods sold was $9.1 million for Q4 2025 and $9.7 million for the full year, including an $8.9 million inventory reserve [11][29] - Research and development expenses decreased to $14.6 million in Q4 2025 from $20.7 million in Q4 2024, reflecting a shift towards commercial operations [11][29] - The net loss for Q4 2025 was $24.8 million, compared to a net loss of $20.9 million in Q4 2024, while the annual net loss decreased to $40.8 million from $148.7 million [11][29] Product Development and Pipeline - The company is advancing its coronary tissue engineered vessel (CTEV) towards a first-in-human study in CABG, with plans to initiate clinical trials in the second half of 2026 [3][8] - The V012 Phase 3 study is designed to assess the efficacy and safety of the acellular tissue engineered vessel (ATEV) for hemodialysis, with interim results expected by early June 2026 [9][11] - Long-term efficacy and safety data for Symvess have been published, demonstrating its durability and low infection rates in various applications [9][11] Market Expansion - Humacyte is actively expanding the commercialization of Symvess in international markets, with a focus on education and evaluation programs for surgeons in Saudi Arabia [3][4] - The company has received multiple Value Analysis Committee (VAC) approvals, with 27 hospitals having ordered Symvess, indicating growing acceptance in the U.S. market [4][11]

Core Insights - Humacyte, Inc. has appointed Rick McElheny as Senior Vice President of Business Development to enhance corporate collaborations and accelerate the commercialization of its regenerative medicine pipeline [1][2] Company Overview - Humacyte is a biotechnology platform company focused on developing universally implantable, bioengineered human tissues at commercial scale [1][4] - The company aims to improve patient lives and transform medical practices through its advanced tissue constructs and organ systems [4] Leadership and Experience - Rick McElheny brings over 15 years of experience in corporate development and alliance management within biopharma, having previously held senior roles at Clearside Biomedical and Vidara Therapeutics [2][3] - His track record includes overseeing high-value licensing and merger transactions, such as the $660 million sale of Vidara Therapeutics and over $250 million in out-licensing transactions at Clearside Biomedical [2] Product Pipeline - Humacyte's pipeline includes products like Symvess® and programs targeting coronary bypass graft surgery and the BioVascular Pancreas for Type 1 diabetes, presenting multiple collaboration opportunities [3] - The company’s acellular tissue engineered vessel (ATEV) received FDA approval for vascular trauma in December 2024 and is in late-stage trials for other vascular applications [4] Regulatory Designations - Humacyte's 6mm ATEV for AV access in hemodialysis is the first to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also been granted Fast Track designation [4] - The ATEV has received priority designation for treating vascular trauma from the U.S. Secretary of Defense [4]

Core Viewpoint - Humacyte, Inc. is set to release its financial results for the quarter and year ended December 31, 2025, on March 27, 2026, and will provide a corporate and financial update during a conference call [1][2]. Company Overview - Humacyte, Inc. is a biotechnology platform company focused on developing universally implantable, bioengineered human tissues at a commercial scale [1][3]. - The company manufactures acellular tissues aimed at treating various diseases, injuries, and chronic conditions [3]. - Humacyte's Biologics License Application for its acellular tissue engineered vessel (ATEV), named Symvess, was approved by the FDA in December 2024 for vascular trauma [3]. - The ATEV is currently undergoing late-stage clinical trials for additional vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease [3]. - The company is preparing for human clinical studies in coronary artery bypass graft surgery and is also in preclinical development for conditions such as type 1 diabetes and pediatric heart disease [3]. - Humacyte's 6mm ATEV for AV access in hemodialysis was the first to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received Fast Track designation [3]. Upcoming Events - The financial results and corporate update will be presented during a conference call scheduled for March 27, 2026, at 8:00 a.m. Eastern Time [2]. - Investors can join the call using specific contact numbers provided for U.S. and international participants [2].

- Purchase commitment is for a minimum of $1.475 million of Symvess product -DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has received a minimum purchase commitment of $1.475 million of the Symvess acellular tissue engineered vessel to facilitate a clinical evaluation and outreach program in hospitals within the King ...

Core Insights - Humacyte, Inc. has secured a credit facility with Avenue Venture Opportunities Fund II, L.P. for up to $77.5 million, aimed at retiring existing debt and providing future financing opportunities [1][2] Financing Details - The credit agreement has a four-year term, with an initial tranche of $40 million fully funded at closing, and two additional tranches totaling up to $37.5 million contingent on certain conditions [1] - Proceeds from the initial tranche are primarily allocated to retire Humacyte's existing debt facility [1] Company Growth Plans - Humacyte plans to expand the use of its product Symvess® in both U.S. and international markets in 2026 [2] - The company anticipates interim results from its V012 Phase 3 trial in dialysis and the initiation of the first human study of its coronary tissue engineered vessel (CTEV) for coronary bypass graft surgery [2] Product Development and Regulatory Status - Humacyte is developing bioengineered human tissues and has received FDA approval for its acellular tissue engineered vessel (ATEV) for vascular trauma in December 2024 [4] - The ATEV is currently in late-stage clinical trials for other vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease [4] - Preclinical development is ongoing for coronary artery bypass grafts, pediatric heart surgery, and treatment of type 1 diabetes [4] Strategic Partnerships - Avenue Venture Opportunities Fund expresses excitement in partnering with Humacyte, highlighting the significant patient needs addressed by Symvess [2][3]

Core Insights - Humacyte, Inc. announced positive two-year results from the V007 Phase 3 clinical trial of its acellular tissue engineered vessel (ATEV) for hemodialysis access, demonstrating superior performance compared to the current gold standard, autogenous fistula, particularly in high-need subgroups [1][2][5] Group 1: Clinical Trial Results - The V007 Phase 3 trial showed that ATEV had a superior duration of use over 24 months compared to autogenous fistula in female, obese, and diabetic patients, who typically have poor outcomes with AV fistula procedures [2][4] - In female patients (n=70), the average duration of ATEV usage was 15.8 months compared to 10.0 months for AV fistula (p<0.0137) [4] - In the target population of females and males with obesity and diabetes (n=110), ATEV had an average duration of access use of 14.8 months versus 9.1 months for AV fistula (p=0.0114) [4] Group 2: Clinical Significance - The ATEV provided a clinically meaningful advantage in early usability and functional patency, enabling faster and more reliable dialysis initiation, especially in high-risk patients [3][5] - The results indicate that ATEV could significantly reduce reliance on catheters for arteriovenous access, which is a major cause of complications and treatment costs in patient care [3][6] Group 3: Safety Profile - After 24 months of follow-up, no unexpected side effects were observed in patients implanted with the ATEV, showing a comparable safety profile to AV fistula with low rates of infection [7] - Although ATEV patients experienced more thrombosis and stenosis events requiring interventions, most cases were successfully treated [7] Group 4: Company Overview - Humacyte is developing a biotechnology platform for universally implantable bioengineered human tissues and has received FDA approval for the ATEV in vascular trauma [9] - The company is also conducting late-stage clinical trials for other vascular applications, including AV access for hemodialysis and peripheral artery disease [9]

Core Viewpoint - Humacyte, Inc. is set to release its financial results for Q3 2025 on November 12, 2025, and will provide a corporate and financial update during a webcast and conference call [1][2]. Company Overview - Humacyte, Inc. is a clinical-stage biotechnology platform company focused on developing universally implantable, bioengineered human tissues at a commercial scale [1][3]. - The company manufactures acellular tissues aimed at treating various diseases, injuries, and chronic conditions [3]. - The FDA approved the Biologics License Application for Humacyte's acellular tissue engineered vessel (ATEV) for vascular trauma in December 2024 [3]. - ATEVs are currently in late-stage clinical trials for additional vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease [3]. - Preclinical development is ongoing for coronary artery bypass grafts, pediatric heart surgery, type 1 diabetes treatment, and other novel cell and tissue applications [3]. - Humacyte's 6mm ATEV for AV access in hemodialysis is notable for being the first product to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received Fast Track designation [3]. - The ATEV has received priority designation for vascular trauma treatment from the U.S. Secretary of Defense [3]. Financial Results Announcement - The financial results for the quarter ending September 30, 2025, will be announced on November 12, 2025, at 8:00 AM ET [2]. - A conference call will be available for U.S. and international investors, with specific dial-in numbers provided [2]. - The webcast will be accessible 15 minutes prior to the call and will be available for replay for at least 30 days [2].

Core Viewpoint - Humacyte, Inc. has entered into a securities purchase agreement to raise approximately $60 million through an oversubscribed registered direct offering of common stock and warrants [1][3]. Group 1: Offering Details - The company will sell 28,436,018 shares of common stock along with warrants to purchase an equal number of shares [2]. - The exercise price for the warrants is set at $2.11 per share, with the warrants becoming exercisable 180 days after issuance and expiring on April 7, 2031 [2]. - The gross proceeds from the offering are estimated to be around $60 million before deducting fees and expenses, with the closing expected on or about October 8, 2025 [3]. Group 2: Regulatory and Legal Framework - The offering is conducted under a "shelf" registration statement on Form S-3, which was filed with the SEC and became effective on September 22, 2025 [4]. - A prospectus supplement detailing the terms of the offering will be filed with the SEC and will be part of the effective registration statement [5]. Group 3: Company Overview - Humacyte, Inc. is focused on developing bioengineered human tissues and advanced tissue constructs aimed at improving patient outcomes and transforming medical practices [8]. - The company has received FDA approval for its acellular tissue engineered vessel (ATEV) for extremity vascular trauma and is conducting late-stage clinical trials for other vascular applications [8]. - Humacyte's ATEV has received multiple designations from the FDA, including Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations [8].

Core Viewpoint - Humacyte, Inc. is set to release its financial results for Q2 2025 on August 11, 2025, and will provide a corporate and financial update during a conference call [1] Group 1: Company Overview - Humacyte, Inc. is a clinical-stage biotechnology platform company focused on developing universally implantable, bioengineered human tissues at commercial scale [2] - The company has received FDA approval for its acellular tissue engineered vessel (ATEV) for vascular trauma in December 2024 and is conducting late-stage clinical trials for other vascular applications [2] - Humacyte's ATEV has received multiple designations, including Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA [2] Group 2: Financial and Conference Call Details - The financial results for the quarter ended June 30, 2025, will be released on August 11, 2025, with a conference call scheduled for 8:00 a.m. ET [1] - Investors can access the conference call via specific dial-in numbers and a conference ID, with a webcast available 15 minutes prior to the call [1]

Core Insights - Humacyte, Inc. is a biotechnology company focused on developing universally implantable, bioengineered human tissues at a commercial scale [1][3] - The company will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, with management available for one-on-one meetings [1][2] Company Overview - Humacyte is developing a disruptive biotechnology platform aimed at improving patient lives and transforming medical practices through acellular tissues for various diseases and conditions [3] - The FDA approved Humacyte's Biologics License Application for the acellular tissue engineered vessel (ATEV) in December 2024, specifically for vascular trauma [3] - ATEVs are in late-stage clinical trials for additional vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease [3] - Preclinical development is ongoing for coronary artery bypass grafts, pediatric heart surgery, type 1 diabetes treatment, and other novel cell and tissue applications [3] - Humacyte's 6mm ATEV for AV access in hemodialysis received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation [3] - The ATEV has also received RMAT designations for urgent arterial repair following extremity vascular trauma and advanced PAD, along with priority designation for vascular trauma treatment from the U.S. Secretary of Defense [3]